Ostia Sciences
Oral and respiratory microbiome biotherapeutic solutions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | CAD393k | Grant | |
| Total Funding | 000k | ||
Related Content
Ostia Sciences Inc. is a Toronto-based biotechnology company that spun out from the University of Toronto in 2020. The company, co-founded by CEO Dr. Abdelahhad Barbour and CSO Dr. Michael Glogauer, focuses on developing oral probiotics and biotherapeutics to address a range of infectious diseases and immune disorders. The firm's name originates from the Latin word "Ostia," meaning mouth, signifying the gateway for many pathogens.
The company's core technology revolves around microbiome-based applications designed to modulate the human microbiome for improved oral and respiratory health. A key product in development is SALI-10, a probiotic based on the company's proprietary phosphorylated lantibiotic technology. This technology, exemplified by the discovery of Salivaricin 10—the world's first phosphorylated antibiotic—provides targeted antimicrobial and pro-immune benefits. Ostia Sciences is preparing for clinical trials for SALI-10 to begin in early 2025, targeting conditions like gingivitis and halitosis as well as respiratory and oral diseases. The company aims to commercialize its probiotic solution by the beginning of 2026.
Ostia Sciences operates in the biotherapeutics field, part of the emerging "Bugs to Drugs" sector. Its business model involves research and development, securing intellectual property, and moving products through clinical trials to commercialization. The company partners with contract development and manufacturing organizations (CDMOs) to scale production. As of July 2025, the company has successfully raised over CAD $1.46 million in seed funding and secured non-dilutive grants from organizations like Natural Products Canada to advance its clinical trials and manufacturing processes.
Keywords: oral probiotics, respiratory health, microbiome therapeutics, biotherapeutics, phosphorylated lantibiotic, SALI-10, infectious diseases, immune modulation, University of Toronto spinout, Bugs to Drugs, Salivaricin 10, antimicrobial, pro-immune, biotechnology, clinical trials, oral care, drug discovery, biopharmaceutical, gut health, healthtech